Correction, October 24, 2026: An earlier version of this article said a Maryland study found false claims in nearly half of ketamine clinic advertising. The study found false statements by up to 4 of 17 advertisers, about 24 percent; larger shares left out adverse effects (7 of 17) or off-label status (10 of 17). The article also described the New York study as using the same method; it catalogued what clinics advertise but did not assess the accuracy of their claims. The headline and article have been revised, and the New York study’s headline findings, which had been described as unavailable, are now reported.

Researchers have published a systematic web search cataloguing clinics that use direct-to-consumer advertising to sell off-label ketamine across the New York metropolitan area, one of the densest healthcare markets in the country. The study comes from a team that includes NYU’s Joseph Palamar, a drug-epidemiology researcher who also serves as deputy director of the federally funded National Drug Early Warning System. It uses a systematic web search similar to one that, run in Maryland, found false claims and widespread missing disclosures about ketamine’s approval status and risks. Unlike the Maryland study, the New York study recorded what clinics advertise but did not judge whether their claims were accurate. It located 233 clinics, 36.5 percent of which prescribed ketamine for at-home use. The value of this kind of study is the baseline: for oversight to work, someone first has to count what is actually being advertised.

Why an ad-mapping study is the right instrument

Ketamine’s off-label market has grown quickly and with little coordinated oversight. Intravenous ketamine is FDA-approved only as an anesthetic; every psychiatric use, delivered in a clinic or via telehealth, is off-label. Esketamine, the related but distinct nasal spray, is FDA-approved for treatment-resistant depression, but only under a Risk Evaluation and Mitigation Strategy that requires in-clinic administration and two hours of monitored observation. Between those two facts sits a large, loosely regulated space: clinics advertising ketamine infusions, sublingual lozenges, and take-home prescriptions for depression, anxiety, PTSD, and pain, direct to consumers, often via telehealth intake with no in-person visit required. A systematic web search, identifying every advertiser in a region and coding what each one claims, is how researchers turn that sprawl into countable data.

What the comparable study found

A study with a similar search method, run in Maryland by researchers at the University of Colorado and Johns Hopkins and published in JAMA Network Open in 2023, is the clearest available preview of what this kind of mapping tends to surface. It identified 17 advertisers operating across 26 locations in a single state, charging $360 to $2,500 per infusion, promoting the drug for depression, PTSD, anxiety, chronic pain, and beyond. The advertising problems were specific and countable: seven of the seventeen advertisers failed to disclose ketamine’s potential for adverse effects, three explicitly and falsely claimed the drug is not addictive, ten did not disclose that the psychiatric use being advertised was off-label, and one falsely claimed FDA approval for treating depression outright. The researchers behind that study also estimated, from compiling national clinic directories, that roughly 800 such clinics operate across the country. Up to 4 of the 17 Maryland advertisers made a false statement. Larger shares left information out: 7 gave no adverse effects and 10 did not say the use was off-label.

Why New York raises the stakes

None of those Maryland-specific figures should be assumed to transfer directly to New York; the new study counted different things and did not test claims for accuracy. What can be said is that the New York metro area is a fundamentally larger and denser market than the one previously studied. That means the study is more likely to surface a large, quantifiable pattern than a handful of outliers, and any oversight gaps it documents affect a correspondingly larger patient population. Applying an established approach to a bigger, more consequential market is exactly the right next step for building the kind of empirical baseline that regulators and platforms eventually have to act on.

Where this study sits in the broader picture

Alongside ketamine’s expansion into new indications sits a countervailing safety literature the desk has tracked: misuse patterns without standardized measurement criteria, and cumulative-exposure hepatotoxicity risk that mostly shows up above psychiatric dosing. Advertising oversight is the third leg of that safety stool, sitting upstream of both: before a patient is ever dosed, what were they told the drug was, how well-established was it claimed to be, and were the risks disclosed at all. A pattern of misleading advertising compounds the other risks, because patients making an expensive, out-of-pocket, high-stakes decision are doing so on the basis of advertising that, in the one comparable region studied, sometimes made false claims and often left out risks.

What This Piece Does and Doesn’t Claim

This piece reports the New York study’s headline counts, its authorship and its method, and uses the Maryland study strictly as an illustrative precedent, clearly labeled as such. The New York study did not assess whether claims were accurate, so it cannot show how often New York clinics make false statements. The Maryland numbers describe Maryland, not New York, and a larger, wealthier, more saturated market could look better or worse. Advertising violations are not the same as clinical harm; a clinic misrepresenting FDA status is a real problem, but it does not by itself mean patients are being harmed, only that they are being poorly informed. And systematic web searches capture what is publicly advertised, not what happens in the clinical encounter itself, which is a narrower and different kind of oversight gap than clinical-quality monitoring would address.

Why Counting the Clinics Is the Real Work

The regulatory conversation around off-label ketamine has mostly proceeded on anecdote, a viral horror story, an FDA warning letter, a lawsuit. What actually enables systematic oversight is unglamorous: someone has to count the clinics and log their claims, and then, as the Maryland study did, check those claims against the facts. The New York study does the first part, and doing it in one of the country’s largest healthcare markets raises the number of patients any resulting oversight action would actually reach. The Maryland baseline found false claims in a minority of advertisers and missing risk and off-label disclosures in many. Whether New York looks similar is now a documented, checkable question rather than a guess, and that is the useful thing this study provides regardless of which way its own numbers land.